HRP20010478A2 - Piperidines as ccr5 modulators - Google Patents
Piperidines as ccr5 modulators Download PDFInfo
- Publication number
- HRP20010478A2 HRP20010478A2 HR20010478A HRP20010478A HRP20010478A2 HR P20010478 A2 HRP20010478 A2 HR P20010478A2 HR 20010478 A HR20010478 A HR 20010478A HR P20010478 A HRP20010478 A HR P20010478A HR P20010478 A2 HRP20010478 A2 HR P20010478A2
- Authority
- HR
- Croatia
- Prior art keywords
- piperidinyl
- phenylpropyl
- group
- oxadiazol
- alkyl
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 479
- 238000000034 method Methods 0.000 claims description 147
- 230000036961 partial effect Effects 0.000 claims description 143
- 125000001424 substituent group Chemical group 0.000 claims description 111
- -1 indazolinyl Chemical group 0.000 claims description 69
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 63
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 52
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 40
- 230000027455 binding Effects 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 37
- 239000000460 chlorine Substances 0.000 claims description 33
- 208000031886 HIV Infections Diseases 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 29
- 229910052731 fluorine Inorganic materials 0.000 claims description 29
- 208000037357 HIV infectious disease Diseases 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 28
- 230000002265 prevention Effects 0.000 claims description 28
- 229910052801 chlorine Inorganic materials 0.000 claims description 26
- 208000030507 AIDS Diseases 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 24
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 21
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 102000019034 Chemokines Human genes 0.000 claims description 18
- 108010012236 Chemokines Proteins 0.000 claims description 18
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 18
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 18
- 125000002971 oxazolyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims description 16
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- 125000001425 triazolyl group Chemical group 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 15
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 108700011778 CCR5 Proteins 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 125000004306 triazinyl group Chemical group 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 7
- 108700012434 CCL3 Proteins 0.000 claims description 7
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 7
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 7
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 5
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 5
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 5
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 5
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 5
- 229960004748 abacavir Drugs 0.000 claims description 5
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 5
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 5
- 229960003205 adefovir dipivoxil Drugs 0.000 claims description 5
- 229960001830 amprenavir Drugs 0.000 claims description 5
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229960002656 didanosine Drugs 0.000 claims description 5
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 5
- 229960003804 efavirenz Drugs 0.000 claims description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
- 229960001936 indinavir Drugs 0.000 claims description 5
- 229940124524 integrase inhibitor Drugs 0.000 claims description 5
- 239000002850 integrase inhibitor Substances 0.000 claims description 5
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 5
- 229960000884 nelfinavir Drugs 0.000 claims description 5
- 229960000689 nevirapine Drugs 0.000 claims description 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- 229960001852 saquinavir Drugs 0.000 claims description 5
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 5
- 229960001203 stavudine Drugs 0.000 claims description 5
- 229960000523 zalcitabine Drugs 0.000 claims description 5
- 229960002555 zidovudine Drugs 0.000 claims description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 4
- 229960002169 plerixafor Drugs 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- VRAJWAGCJIXJHQ-WCQYABFASA-N 1-(5-bromopyridin-2-yl)-3-[(1r,2r)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea Chemical compound CCC(=O)C1=CC=C(F)C([C@@H]2[C@@H](C2)NC(=O)NC=2N=CC(Br)=CC=2)=C1O VRAJWAGCJIXJHQ-WCQYABFASA-N 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 108010036239 CD4-IgG(2) Proteins 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Chemical group 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 102100034343 Integrase Human genes 0.000 claims description 3
- 101710203526 Integrase Proteins 0.000 claims description 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 3
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 125000002785 azepinyl group Chemical group 0.000 claims description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 229960005319 delavirdine Drugs 0.000 claims description 3
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 108010038379 sargramostim Proteins 0.000 claims description 3
- 229960002530 sargramostim Drugs 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
- 229960000838 tipranavir Drugs 0.000 claims description 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 3
- NKPHEWJJTGPRSL-GXTWGEPZSA-N 1-(5-cyanopyridin-2-yl)-3-[(1r,2r)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea Chemical compound CCC(=O)C1=CC=C(F)C([C@@H]2[C@@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O NKPHEWJJTGPRSL-GXTWGEPZSA-N 0.000 claims description 2
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 2
- 206010058874 Viraemia Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 238000012790 confirmation Methods 0.000 claims description 2
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- XSWFUEQAQWKUFP-VWLOTQADSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-(3-fluorophenyl)propyl]cyclobutanecarboxamide Chemical compound FC1=CC=CC([C@H](CCN2CCC(CC2)C=2ON=C(CC=3C=CC=CC=3)N=2)NC(=O)C2CCC2)=C1 XSWFUEQAQWKUFP-VWLOTQADSA-N 0.000 claims description 2
- FMNCYTUOWSABQY-SANMLTNESA-N n-[(1s)-3-[4-[3-(1-benzofuran-5-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1([C@H](CCN2CCC(CC2)C=2ON=C(CC=3C=C4C=COC4=CC=3)N=2)NC(=O)C2CCC2)=CC=CC=C1 FMNCYTUOWSABQY-SANMLTNESA-N 0.000 claims description 2
- ACZOKWULQUZSGC-UHFFFAOYSA-N n-[1-phenyl-3-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1C(ON=1)=NC=1C1=CC=CC=C1 ACZOKWULQUZSGC-UHFFFAOYSA-N 0.000 claims description 2
- QJJBGJCPVNIDQZ-UHFFFAOYSA-N n-[3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CC1=NOC(C2CCN(CCC(NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 QJJBGJCPVNIDQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000006490 viral transcription Effects 0.000 claims description 2
- SXPUVBFQXJHYNS-UHFFFAOYSA-N α-furil Chemical compound C=1C=COC=1C(=O)C(=O)C1=CC=CO1 SXPUVBFQXJHYNS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001627 lamivudine Drugs 0.000 claims 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical group N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 2
- IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 claims 2
- 229940125777 fusion inhibitor Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- BSNVIOWZGURDSN-VWLOTQADSA-N 1-[(3s)-3-(cyclobutanecarbonylamino)-3-phenylpropyl]-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-n-methylpiperidine-4-carboxamide Chemical compound N([C@@H](CCN1CCC(CC1)(C(=O)NC)C=1ON=C(CC=2C=CC(F)=CC=2)N=1)C=1C=CC=CC=1)C(=O)C1CCC1 BSNVIOWZGURDSN-VWLOTQADSA-N 0.000 claims 1
- QFHSYMOLFCOPOA-SANMLTNESA-N 1-acetyl-n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(C=2ON=C(CC=3C=CC=CC=3)N=2)CC1 QFHSYMOLFCOPOA-SANMLTNESA-N 0.000 claims 1
- AUCSKVOUXKXEJI-MHZLTWQESA-N 1-acetyl-n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(N2N=C(CC=3C=CC=CC=3)N=C2)CC1 AUCSKVOUXKXEJI-MHZLTWQESA-N 0.000 claims 1
- LPAXMSWGSXSNEF-NDEPHWFRSA-N 1-acetyl-n-[(1s)-3-[4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(N2C(=NC(CC=3C=CC=CC=3)=N2)C)CC1 LPAXMSWGSXSNEF-NDEPHWFRSA-N 0.000 claims 1
- VVSBCPXJWZHUIT-MHZLTWQESA-N 1-acetyl-n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-triazol-1-yl]piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(N2N=C(CC=3C=CC(F)=CC=3)N=C2)CC1 VVSBCPXJWZHUIT-MHZLTWQESA-N 0.000 claims 1
- HXPAOXNZEXMLAA-MHZLTWQESA-N 1-acetyl-n-[(1s)-3-[4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(C=2ON=C(CC=3C=CC(NS(C)(=O)=O)=CC=3)N=2)CC1 HXPAOXNZEXMLAA-MHZLTWQESA-N 0.000 claims 1
- BPNYEWDWYSQXHE-SANMLTNESA-N 1-acetyl-n-[(1s)-3-[4-cyano-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)C)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(C=2ON=C(CC=3C=CC(F)=CC=3)N=2)(C#N)CC1 BPNYEWDWYSQXHE-SANMLTNESA-N 0.000 claims 1
- YCTMBKMREFCPTB-SANMLTNESA-N 1-amino-n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]cyclopentane-1-carboxamide Chemical compound N([C@@H](CCN1CCC(CC1)N1N=C(CC=2C=CC=CC=2)N=C1)C=1C=CC=CC=1)C(=O)C1(N)CCCC1 YCTMBKMREFCPTB-SANMLTNESA-N 0.000 claims 1
- AXKKNCYAJWOIPI-MHZLTWQESA-N 1-amino-n-[(1s)-3-[4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]cyclopentane-1-carboxamide Chemical compound N=1N(C2CCN(CC[C@H](NC(=O)C3(N)CCCC3)C=3C=CC=CC=3)CC2)C(C)=NC=1CC1=CC=CC=C1 AXKKNCYAJWOIPI-MHZLTWQESA-N 0.000 claims 1
- AAWCZPAOUJTICR-QFIPXVFZSA-N 3,3,3-trifluoro-n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]propanamide Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)CC(F)(F)F)C=3C=CC=CC=3)CC2)=N1 AAWCZPAOUJTICR-QFIPXVFZSA-N 0.000 claims 1
- UTYKMUCGVBVBQZ-VWLOTQADSA-N 3-[[5-[1-[(3s)-3-(cyclobutanecarbonylamino)-3-phenylpropyl]piperidin-4-yl]-1,2,4-oxadiazol-3-yl]methyl]benzamide Chemical compound NC(=O)C1=CC=CC(CC=2N=C(ON=2)C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=C1 UTYKMUCGVBVBQZ-VWLOTQADSA-N 0.000 claims 1
- FGDVGHLGDKLGLH-SANMLTNESA-N ethyl 4-(3-benzyl-1,2,4-oxadiazol-5-yl)-1-[(3s)-3-(cyclobutanecarbonylamino)-3-phenylpropyl]piperidine-4-carboxylate Chemical compound N([C@@H](CCN1CCC(CC1)(C(=O)OCC)C=1ON=C(CC=2C=CC=CC=2)N=1)C=1C=CC=CC=1)C(=O)C1CCC1 FGDVGHLGDKLGLH-SANMLTNESA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- XCYSKMZKBBDLTI-VWLOTQADSA-N n-[(1s)-1-phenyl-3-[4-[3-[(3-sulfamoylphenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound NS(=O)(=O)C1=CC=CC(CC=2N=C(ON=2)C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=C1 XCYSKMZKBBDLTI-VWLOTQADSA-N 0.000 claims 1
- BVEWXFYYSMWVMC-VWLOTQADSA-N n-[(1s)-1-phenyl-3-[4-[3-[(4-sulfamoylphenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 BVEWXFYYSMWVMC-VWLOTQADSA-N 0.000 claims 1
- NLIUYDARAPVIAI-VWLOTQADSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)-4-cyanopiperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1(C#N)C(ON=1)=NC=1CC1=CC=CC=C1 NLIUYDARAPVIAI-VWLOTQADSA-N 0.000 claims 1
- WQPJASBOJFGUAL-VWLOTQADSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-(3-fluorophenyl)propyl]-2-cyclopropylacetamide Chemical compound FC1=CC=CC([C@H](CCN2CCC(CC2)C=2ON=C(CC=3C=CC=CC=3)N=2)NC(=O)CC2CC2)=C1 WQPJASBOJFGUAL-VWLOTQADSA-N 0.000 claims 1
- URDSLQZCRIMVLW-VWLOTQADSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]-1-methoxycyclobutane-1-carboxamide Chemical compound N([C@@H](CCN1CCC(CC1)C=1ON=C(CC=2C=CC=CC=2)N=1)C=1C=CC=CC=1)C(=O)C1(OC)CCC1 URDSLQZCRIMVLW-VWLOTQADSA-N 0.000 claims 1
- QYAVGLXXFMQEDK-VWLOTQADSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=C1 QYAVGLXXFMQEDK-VWLOTQADSA-N 0.000 claims 1
- LKYJJULDTXIAIB-SANMLTNESA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound C([C@H](NC(=O)C1CCOCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=C1 LKYJJULDTXIAIB-SANMLTNESA-N 0.000 claims 1
- SNFRZVMBDNNQAC-MHZLTWQESA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]-1-propanoylazetidine-3-carboxamide Chemical compound C1N(C(=O)CC)CC1C(=O)N[C@H](C=1C=CC=CC=1)CCN1CCC(N2N=C(CC=3C=CC=CC=3)N=C2)CC1 SNFRZVMBDNNQAC-MHZLTWQESA-N 0.000 claims 1
- HJIFNRLOZKIKIM-SANMLTNESA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=CC=C1 HJIFNRLOZKIKIM-SANMLTNESA-N 0.000 claims 1
- IGZIYEKMZDQZAW-MHZLTWQESA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound C([C@H](NC(=O)C1CCOCC1)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=CC=C1 IGZIYEKMZDQZAW-MHZLTWQESA-N 0.000 claims 1
- VREAHNHGPJTQSG-JKGBFCRXSA-N n-[(1s)-3-[4-(3-benzyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]oxolane-3-carboxamide Chemical compound C([C@H](NC(=O)C1COCC1)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=CC=C1 VREAHNHGPJTQSG-JKGBFCRXSA-N 0.000 claims 1
- CIIBWDKATGZKGV-NDEPHWFRSA-N n-[(1s)-3-[4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound N=1N(C2CCN(CC[C@H](NC(=O)C3CCOCC3)C=3C=CC=CC=3)CC2)C(C)=NC=1CC1=CC=CC=C1 CIIBWDKATGZKGV-NDEPHWFRSA-N 0.000 claims 1
- ZVFJBHTUSHYHKW-GPNIZQGCSA-N n-[(1s)-3-[4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidin-1-yl]-1-phenylpropyl]oxolane-3-carboxamide Chemical compound N=1N(C2CCN(CC[C@H](NC(=O)C3COCC3)C=3C=CC=CC=3)CC2)C(C)=NC=1CC1=CC=CC=C1 ZVFJBHTUSHYHKW-GPNIZQGCSA-N 0.000 claims 1
- RYABNTCCFFMRSK-MHZLTWQESA-N n-[(1s)-3-[4-(3-benzyl-5-methyl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CN(CC[C@H](NC(=O)C2CCC2)C=2C=CC=CC=2)CCC1N1C(C)=NN=C1CC1=CC=CC=C1 RYABNTCCFFMRSK-MHZLTWQESA-N 0.000 claims 1
- LKDHPSKAANCOIF-SANMLTNESA-N n-[(1s)-3-[4-(5-benzyl-1-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CN1N=C(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)N=C1CC1=CC=CC=C1 LKDHPSKAANCOIF-SANMLTNESA-N 0.000 claims 1
- HARJVSVCHMBZOH-SANMLTNESA-N n-[(1s)-3-[4-(5-benzyl-2-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound N1=C(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)N(C)N=C1CC1=CC=CC=C1 HARJVSVCHMBZOH-SANMLTNESA-N 0.000 claims 1
- ILRLGJAQLZEMBZ-SANMLTNESA-N n-[(1s)-3-[4-(5-benzyl-4-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound N=1N=C(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)N(C)C=1CC1=CC=CC=C1 ILRLGJAQLZEMBZ-SANMLTNESA-N 0.000 claims 1
- DMLWUZBEVFKJHU-DEOSSOPVSA-N n-[(1s)-3-[4-[3-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1([C@H](CCN2CCC(CC2)C=2ON=C(CC=3C=C4OCOC4=CC=3)N=2)NC(=O)C2CCC2)=CC=CC=C1 DMLWUZBEVFKJHU-DEOSSOPVSA-N 0.000 claims 1
- CLDCULWYNJACLU-QFIPXVFZSA-N n-[(1s)-3-[4-[3-(2-methylpropyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CC(C)CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 CLDCULWYNJACLU-QFIPXVFZSA-N 0.000 claims 1
- XGBLMCPTKZDOSF-QHCPKHFHSA-N n-[(1s)-3-[4-[3-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CN1CCOCC1 XGBLMCPTKZDOSF-QHCPKHFHSA-N 0.000 claims 1
- DBBCXKJSNFDBHF-VWLOTQADSA-N n-[(1s)-3-[4-[3-[(4-acetylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CN(C(=O)C)CCN1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 DBBCXKJSNFDBHF-VWLOTQADSA-N 0.000 claims 1
- ZMOSSMLTPKOTCQ-SANMLTNESA-N n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCOCC3)C=3C=CC=CC=3)CC2)=N1 ZMOSSMLTPKOTCQ-SANMLTNESA-N 0.000 claims 1
- YBSQQBKTQPXQKO-DEOSSOPVSA-N n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-triazol-1-yl]piperidin-1-yl]-1-phenylpropyl]-2-methoxyacetamide Chemical compound C([C@H](NC(=O)COC)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=C(F)C=C1 YBSQQBKTQPXQKO-DEOSSOPVSA-N 0.000 claims 1
- YXBYUXARDWFTTE-VWLOTQADSA-N n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-triazol-1-yl]piperidin-1-yl]-1-phenylpropyl]-3-methoxypropanamide Chemical compound C([C@H](NC(=O)CCOC)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=C(F)C=C1 YXBYUXARDWFTTE-VWLOTQADSA-N 0.000 claims 1
- PGEHNYUEZUMREH-VWLOTQADSA-N n-[(1s)-3-[4-[3-[[2-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 PGEHNYUEZUMREH-VWLOTQADSA-N 0.000 claims 1
- QTQTXBNPHZZABV-SANMLTNESA-N n-[(1s)-3-[4-[3-[[3-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC=2N=C(ON=2)C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=C1 QTQTXBNPHZZABV-SANMLTNESA-N 0.000 claims 1
- JRCVLGDHPSOOND-MHZLTWQESA-N n-[(1s)-3-[4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCOCC3)C=3C=CC=CC=3)CC2)=N1 JRCVLGDHPSOOND-MHZLTWQESA-N 0.000 claims 1
- VQYRMPZOXFQVOP-NDEPHWFRSA-N n-[(1s)-3-[4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-triazol-1-yl]piperidin-1-yl]-1-phenylpropyl]oxane-4-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC1=NN(C2CCN(CC[C@H](NC(=O)C3CCOCC3)C=3C=CC=CC=3)CC2)C=N1 VQYRMPZOXFQVOP-NDEPHWFRSA-N 0.000 claims 1
- MTHNAOMOISJIEU-VWLOTQADSA-N n-[(1s)-3-[4-cyano-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]-2-cyclopropylacetamide Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2(CCN(CC[C@H](NC(=O)CC3CC3)C=3C=CC=CC=3)CC2)C#N)=N1 MTHNAOMOISJIEU-VWLOTQADSA-N 0.000 claims 1
- PNXJYEQLVWOQLR-QFIPXVFZSA-N n-[(1s)-3-[4-cyano-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]-3,3,3-trifluoropropanamide Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2(CCN(CC[C@H](NC(=O)CC(F)(F)F)C=3C=CC=CC=3)CC2)C#N)=N1 PNXJYEQLVWOQLR-QFIPXVFZSA-N 0.000 claims 1
- YXFJXHDCNONXMY-UHFFFAOYSA-N n-[1,1-diphenyl-3-[4-(1,2,4-triazol-4-yl)piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)CCN(CC1)CCC1N1C=NN=C1 YXFJXHDCNONXMY-UHFFFAOYSA-N 0.000 claims 1
- BNUDGISXPWXIPC-UHFFFAOYSA-N n-[1-phenyl-3-[4-(5-phenyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1C(N=1)=NOC=1C1=CC=CC=C1 BNUDGISXPWXIPC-UHFFFAOYSA-N 0.000 claims 1
- IBDCOCXDJHTUHA-UHFFFAOYSA-N n-[3-[4-(1-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CN1C=NC(C2CCN(CCC(NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 IBDCOCXDJHTUHA-UHFFFAOYSA-N 0.000 claims 1
- XIIMLQNTNWEIHO-UHFFFAOYSA-N n-[3-[4-(2-methyl-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CN1N=CN=C1C1CCN(CCC(NC(=O)C2CCC2)C=2C=CC=CC=2)CC1 XIIMLQNTNWEIHO-UHFFFAOYSA-N 0.000 claims 1
- SRYGGSYASXWGOY-UHFFFAOYSA-N n-[3-[4-(3,5-dimethyl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound CC1=NN=C(C)N1C1CCN(CCC(NC(=O)C2CCC2)C=2C=CC=CC=2)CC1 SRYGGSYASXWGOY-UHFFFAOYSA-N 0.000 claims 1
- QYAVGLXXFMQEDK-UHFFFAOYSA-N n-[3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=C1 QYAVGLXXFMQEDK-UHFFFAOYSA-N 0.000 claims 1
- WEQODXBTPSTLAA-UHFFFAOYSA-N n-[3-[4-(3-methyl-5-phenyl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CN(CCC(NC(=O)C2CCC2)C=2C=CC=CC=2)CCC1N1C(C)=NN=C1C1=CC=CC=C1 WEQODXBTPSTLAA-UHFFFAOYSA-N 0.000 claims 1
- WJRHWKLKYSTKDD-UHFFFAOYSA-N n-[3-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1C(N=1)=NOC=1CC1=CC=CC=C1 WJRHWKLKYSTKDD-UHFFFAOYSA-N 0.000 claims 1
- UOXDZJHIXYNMQM-UHFFFAOYSA-N n-[3-[4-(5-benzyl-1h-1,2,4-triazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1C(N=1)=NNC=1CC1=CC=CC=C1 UOXDZJHIXYNMQM-UHFFFAOYSA-N 0.000 claims 1
- VOLKYJGHYYEMMU-UHFFFAOYSA-N n-[3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound O1C(C)=NC(C2CCN(CCC(NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 VOLKYJGHYYEMMU-UHFFFAOYSA-N 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 629
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 264
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 250
- 238000002360 preparation method Methods 0.000 description 226
- 230000002829 reductive effect Effects 0.000 description 184
- 239000000243 solution Substances 0.000 description 180
- 238000005160 1H NMR spectroscopy Methods 0.000 description 143
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 130
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 239000003921 oil Substances 0.000 description 103
- 235000019198 oils Nutrition 0.000 description 103
- 239000002904 solvent Substances 0.000 description 99
- 239000011541 reaction mixture Substances 0.000 description 90
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 82
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 81
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 69
- 239000000203 mixture Substances 0.000 description 66
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 65
- 235000019341 magnesium sulphate Nutrition 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- 239000007787 solid Substances 0.000 description 57
- 239000003480 eluent Substances 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- 229910021529 ammonia Inorganic materials 0.000 description 41
- 239000012267 brine Substances 0.000 description 41
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 41
- 238000010992 reflux Methods 0.000 description 40
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 36
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 36
- 238000010898 silica gel chromatography Methods 0.000 description 36
- 239000010410 layer Substances 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 229920006395 saturated elastomer Polymers 0.000 description 34
- 229910000029 sodium carbonate Inorganic materials 0.000 description 34
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
- 229960000583 acetic acid Drugs 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 21
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 239000006260 foam Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 102000009410 Chemokine receptor Human genes 0.000 description 17
- 108050000299 Chemokine receptor Proteins 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000004587 chromatography analysis Methods 0.000 description 17
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- 108010017088 CCR5 Receptors Proteins 0.000 description 13
- 102000004274 CCR5 Receptors Human genes 0.000 description 13
- 238000009833 condensation Methods 0.000 description 13
- 230000005494 condensation Effects 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 238000007363 ring formation reaction Methods 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 239000003513 alkali Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 150000003512 tertiary amines Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 6
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- 102000001902 CC Chemokines Human genes 0.000 description 5
- 108010040471 CC Chemokines Proteins 0.000 description 5
- 108010055166 Chemokine CCL5 Proteins 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101710188315 Protein X Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000005932 reductive alkylation reaction Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 4
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000008484 agonism Effects 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical class C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 3
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- ZEONASHSZKLJGT-UHFFFAOYSA-N n'-hydroxy-2-pyridin-3-ylethanimidamide Chemical compound ON=C(N)CC1=CC=CN=C1 ZEONASHSZKLJGT-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- XSGMGAINOILNJR-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methyl-3-tritylsulfanylbutanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(O)=O)C(C)(C)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XSGMGAINOILNJR-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 2
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 2
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 2
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 2
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- 208000005074 Retroviridae Infections Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- OREKVJOKMUMFKI-UHFFFAOYSA-N ethyl 1-benzyl-4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2ON=C(CC=3C=CC=CC=3)N=2)CCN1CC1=CC=CC=C1 OREKVJOKMUMFKI-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 2
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940071103 sulfosalicylate Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FQFYDAOTUGFLHK-NRFANRHFSA-N (1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropan-1-amine Chemical compound C([C@H](N)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=C1 FQFYDAOTUGFLHK-NRFANRHFSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- GWKIPRVERALPRD-ZDUSSCGKSA-N (s)-4-isopropoxycarbonyl-6-methoxy-3-methylthiomethyl-3,4-dihydroquinoxalin-2(1h)-thione Chemical compound N1C(=S)[C@H](CSC)N(C(=O)OC(C)C)C2=CC(OC)=CC=C21 GWKIPRVERALPRD-ZDUSSCGKSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- NCADHSLPNSTDMJ-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(C(O)=O)C1 NCADHSLPNSTDMJ-UHFFFAOYSA-N 0.000 description 1
- YBZCSKVLXBOFSL-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CCCC1 YBZCSKVLXBOFSL-UHFFFAOYSA-N 0.000 description 1
- WIJCBKJTUCNEFE-SFHVURJKSA-N 1-[(3S)-3-(cyclobutanecarbonylamino)-3-phenylpropyl]piperidine-4-carboxylic acid Chemical compound C1(CCC1)C(=O)N[C@@H](CCN1CCC(CC1)C(=O)O)C1=CC=CC=C1 WIJCBKJTUCNEFE-SFHVURJKSA-N 0.000 description 1
- LZENKZHDZXCPCO-NRFANRHFSA-N 1-[(3s)-3-amino-3-phenylpropyl]-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-4-carbonitrile Chemical compound C([C@H](N)C=1C=CC=CC=1)CN(CC1)CCC1(C#N)C(ON=1)=NC=1CC1=CC=C(F)C=C1 LZENKZHDZXCPCO-NRFANRHFSA-N 0.000 description 1
- VLOZFQJTAXANDZ-UHFFFAOYSA-N 1-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCC1C1=NC(CC=2C=CC=CC=2)=NO1 VLOZFQJTAXANDZ-UHFFFAOYSA-N 0.000 description 1
- YFWJZEMJJMOQAC-UHFFFAOYSA-N 1-acetylazetidine-3-carboxylic acid Chemical compound CC(=O)N1CC(C(O)=O)C1 YFWJZEMJJMOQAC-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- ZUNHJNQDVSDQRU-UHFFFAOYSA-N 1-benzyl-4-(1,2,4-triazol-4-yl)piperidine Chemical compound C=1C=CC=CC=1CN(CC1)CCC1N1C=NN=C1 ZUNHJNQDVSDQRU-UHFFFAOYSA-N 0.000 description 1
- RWPHUHNYHMJJMI-UHFFFAOYSA-N 1-benzyl-4-(1-methyl-1,2,4-triazol-3-yl)piperidine Chemical compound CN1C=NC(C2CCN(CC=3C=CC=CC=3)CC2)=N1 RWPHUHNYHMJJMI-UHFFFAOYSA-N 0.000 description 1
- BOGIWZAIICTRLH-UHFFFAOYSA-N 1-benzyl-4-(2-methyl-1,2,4-triazol-3-yl)piperidine Chemical compound CN1N=CN=C1C1CCN(CC=2C=CC=CC=2)CC1 BOGIWZAIICTRLH-UHFFFAOYSA-N 0.000 description 1
- AOKWKTBXLHHQQP-UHFFFAOYSA-N 1-benzyl-4-(3,5-dimethyl-1,2,4-triazol-4-yl)piperidine Chemical compound CC1=NN=C(C)N1C1CCN(CC=2C=CC=CC=2)CC1 AOKWKTBXLHHQQP-UHFFFAOYSA-N 0.000 description 1
- HGSBWHMQICIUOU-UHFFFAOYSA-N 1-benzyl-4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidine-4-carbonitrile Chemical compound C1CC(C#N)(C=2ON=C(CC=3C=CC=CC=3)N=2)CCN1CC1=CC=CC=C1 HGSBWHMQICIUOU-UHFFFAOYSA-N 0.000 description 1
- FEYHUFVTSDDTRW-UHFFFAOYSA-N 1-benzyl-4-(5-benzyl-4-methyl-1,2,4-triazol-3-yl)piperidine Chemical compound N=1N=C(C2CCN(CC=3C=CC=CC=3)CC2)N(C)C=1CC1=CC=CC=C1 FEYHUFVTSDDTRW-UHFFFAOYSA-N 0.000 description 1
- YYRQBWOYYXCRSX-UHFFFAOYSA-N 1-benzyl-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-4-carbonitrile Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2(CCN(CC=3C=CC=CC=3)CC2)C#N)=N1 YYRQBWOYYXCRSX-UHFFFAOYSA-N 0.000 description 1
- MKQRPOKJNOOUIN-UHFFFAOYSA-N 1-benzyl-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)CCN1CC1=CC=CC=C1 MKQRPOKJNOOUIN-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 1-benzylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1CC1=CC=CC=C1 ZMVSVQMWFTZSJQ-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
- XCBNHDSVRQZWLH-UHFFFAOYSA-N 1-hydroxycyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(O)CCC1 XCBNHDSVRQZWLH-UHFFFAOYSA-N 0.000 description 1
- ZKGYKYOWKFMUGF-UHFFFAOYSA-N 1-methoxycyclobutane-1-carboxylic acid Chemical compound COC1(C(O)=O)CCC1 ZKGYKYOWKFMUGF-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- ZKRDQLBHUZNPGZ-UHFFFAOYSA-N 1-tert-butyl-3-nitrobenzene Chemical compound CC(C)(C)C1=CC=CC([N+]([O-])=O)=C1 ZKRDQLBHUZNPGZ-UHFFFAOYSA-N 0.000 description 1
- LHVJSDFNMHTNKM-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]ethanone Chemical compound CC1=NOC(C2CCN(CC2)C(=O)C(F)(F)F)=N1 LHVJSDFNMHTNKM-UHFFFAOYSA-N 0.000 description 1
- AVBWYVSWDDWPQJ-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCC1C1=NC(C=2C=CC=CC=2)=NO1 AVBWYVSWDDWPQJ-UHFFFAOYSA-N 0.000 description 1
- JOIBFUYKGAMUQD-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C1=NOC(C2CCN(CC2)C(=O)C(F)(F)F)=N1 JOIBFUYKGAMUQD-UHFFFAOYSA-N 0.000 description 1
- MTOPWQGATGWIKS-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]ethanone Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2CCN(CC2)C(=O)C(F)(F)F)=N1 MTOPWQGATGWIKS-UHFFFAOYSA-N 0.000 description 1
- RYABFFHYWJMLAU-UHFFFAOYSA-N 2-(1-benzofuran-5-yl)-n'-hydroxyethanimidamide Chemical compound ON=C(N)CC1=CC=C2OC=CC2=C1 RYABFFHYWJMLAU-UHFFFAOYSA-N 0.000 description 1
- LAUKCBLGPOGMJR-UHFFFAOYSA-N 2-(1-benzofuran-5-yl)acetonitrile Chemical compound N#CCC1=CC=C2OC=CC2=C1 LAUKCBLGPOGMJR-UHFFFAOYSA-N 0.000 description 1
- YIZRGZCXUWSHLN-UHFFFAOYSA-N 2-(3-aminophenyl)acetonitrile Chemical compound NC1=CC=CC(CC#N)=C1 YIZRGZCXUWSHLN-UHFFFAOYSA-N 0.000 description 1
- LXUAMTRFNLOQKD-UHFFFAOYSA-N 2-(3-benzyl-1,2,4-oxadiazol-5-yl)acetonitrile Chemical compound O1C(CC#N)=NC(CC=2C=CC=CC=2)=N1 LXUAMTRFNLOQKD-UHFFFAOYSA-N 0.000 description 1
- WAVKEPUFQMUGBP-UHFFFAOYSA-N 2-(3-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=CC(CC#N)=C1 WAVKEPUFQMUGBP-UHFFFAOYSA-N 0.000 description 1
- ZIWMVSSFCVHWIU-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)acetonitrile Chemical compound CC(=O)N1CCN(CC#N)CC1 ZIWMVSSFCVHWIU-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical compound NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- MLNLOCIMTRRCHX-UHFFFAOYSA-N 2-(4-chlorophenyl)-n'-hydroxyethanimidamide Chemical compound ON=C(N)CC1=CC=C(Cl)C=C1 MLNLOCIMTRRCHX-UHFFFAOYSA-N 0.000 description 1
- RNHKXHKUKJXLAU-UHFFFAOYSA-N 2-(4-methylphenyl)acetonitrile Chemical compound CC1=CC=C(CC#N)C=C1 RNHKXHKUKJXLAU-UHFFFAOYSA-N 0.000 description 1
- JDYLDUDVFUSPCU-UHFFFAOYSA-N 2-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]acetonitrile Chemical compound C1=CC(F)=CC=C1CC1=NOC(CC#N)=N1 JDYLDUDVFUSPCU-UHFFFAOYSA-N 0.000 description 1
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HGVYYGIMDHYGFJ-UHFFFAOYSA-N 2-phenyl-5-piperidin-4-yl-1,3,4-oxadiazole Chemical compound C1CNCCC1C1=NN=C(C=2C=CC=CC=2)O1 HGVYYGIMDHYGFJ-UHFFFAOYSA-N 0.000 description 1
- KNSLGPATJQAECH-UHFFFAOYSA-N 2-phenylacetamide;hydrochloride Chemical compound Cl.NC(=O)CC1=CC=CC=C1 KNSLGPATJQAECH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FPTCVTJCJMVIDV-UHFFFAOYSA-N 2-phenylacetohydrazide Chemical compound NNC(=O)CC1=CC=CC=C1 FPTCVTJCJMVIDV-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- UGOKGICLGOQAFS-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-piperidin-4-yl-1,2,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1C1=NOC(C2CCNCC2)=N1 UGOKGICLGOQAFS-UHFFFAOYSA-N 0.000 description 1
- UMHPWOVPACYGPY-UHFFFAOYSA-N 3-(cyanomethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CC#N)=C1 UMHPWOVPACYGPY-UHFFFAOYSA-N 0.000 description 1
- DATIHVJZEPOWPT-UHFFFAOYSA-N 3-(cyanomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CC#N)=C1 DATIHVJZEPOWPT-UHFFFAOYSA-N 0.000 description 1
- MTOGPZVWNYUYGK-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(methoxymethyl)piperidin-4-yl]-1,2,4-oxadiazole Chemical compound N=1C(CC=2C=CC(F)=CC=2)=NOC=1C1(COC)CCNCC1 MTOGPZVWNYUYGK-UHFFFAOYSA-N 0.000 description 1
- QIDGMJYADBGLCE-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-piperidin-4-yl-1,2,4-oxadiazole Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2CCNCC2)=N1 QIDGMJYADBGLCE-UHFFFAOYSA-N 0.000 description 1
- UJOYFRCOTPUKAK-UHFFFAOYSA-N 3-ammonio-3-phenylpropanoate Chemical compound [O-]C(=O)CC([NH3+])C1=CC=CC=C1 UJOYFRCOTPUKAK-UHFFFAOYSA-N 0.000 description 1
- NKAWZEXAFWZNLV-UHFFFAOYSA-N 3-benzyl-5-piperidin-4-yl-1,2,4-oxadiazole Chemical compound C=1C=CC=CC=1CC(N=1)=NOC=1C1CCNCC1 NKAWZEXAFWZNLV-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- AXFMQUPVIHSGJT-UHFFFAOYSA-N 3-o-[(1-amino-2-phenylethylidene)amino] 1-o-ethyl propanedioate Chemical compound CCOC(=O)CC(=O)ON=C(N)CC1=CC=CC=C1 AXFMQUPVIHSGJT-UHFFFAOYSA-N 0.000 description 1
- FRSNRGPKFYZBJA-UHFFFAOYSA-N 3-phenyl-5-piperidin-4-yl-1,2,4-oxadiazole Chemical compound C1CNCCC1C1=NC(C=2C=CC=CC=2)=NO1 FRSNRGPKFYZBJA-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- BBVLSXSQSFFLQL-UHFFFAOYSA-N 4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidine-4-carbonitrile Chemical compound N=1C(CC=2C=CC=CC=2)=NOC=1C1(C#N)CCNCC1 BBVLSXSQSFFLQL-UHFFFAOYSA-N 0.000 description 1
- BYYQZONONXPRPU-UHFFFAOYSA-N 4-(3-benzyl-1,2,4-triazol-1-yl)piperidine Chemical compound C=1C=CC=CC=1CC(=N1)N=CN1C1CCNCC1 BYYQZONONXPRPU-UHFFFAOYSA-N 0.000 description 1
- KPBVLDPLGFSTLM-UHFFFAOYSA-N 4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidine Chemical compound N=1N(C2CCNCC2)C(C)=NC=1CC1=CC=CC=C1 KPBVLDPLGFSTLM-UHFFFAOYSA-N 0.000 description 1
- WANWKMMOHKQMIO-UHFFFAOYSA-N 4-(3-benzyl-5-methyl-1,2,4-triazol-4-yl)piperidine Chemical compound C1CNCCC1N1C(C)=NN=C1CC1=CC=CC=C1 WANWKMMOHKQMIO-UHFFFAOYSA-N 0.000 description 1
- KYBNVONFYDZCDZ-UHFFFAOYSA-N 4-(3-methyl-5-phenyl-1,2,4-triazol-4-yl)piperidine Chemical compound C1CNCCC1N1C(C)=NN=C1C1=CC=CC=C1 KYBNVONFYDZCDZ-UHFFFAOYSA-N 0.000 description 1
- YMYRTSCAUQDTOR-UHFFFAOYSA-N 4-(5-benzyl-1h-1,2,4-triazol-3-yl)piperidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CC(NN=1)=NC=1C1CCNCC1 YMYRTSCAUQDTOR-UHFFFAOYSA-N 0.000 description 1
- WVKSPKMUCUWFBD-UHFFFAOYSA-N 4-(5-benzyl-4-methyl-1,2,4-triazol-3-yl)piperidine Chemical compound N=1N=C(C2CCNCC2)N(C)C=1CC1=CC=CC=C1 WVKSPKMUCUWFBD-UHFFFAOYSA-N 0.000 description 1
- CQQSQBRPAJSTFB-UHFFFAOYSA-N 4-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-N 0.000 description 1
- KBUKNUOQYOMHHU-UHFFFAOYSA-N 4-(cyanomethyl)benzamide Chemical compound NC(=O)C1=CC=C(CC#N)C=C1 KBUKNUOQYOMHHU-UHFFFAOYSA-N 0.000 description 1
- KMDZAPVMOLFJLY-UHFFFAOYSA-N 4-(cyanomethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(CC#N)C=C1 KMDZAPVMOLFJLY-UHFFFAOYSA-N 0.000 description 1
- RSGBXCFAYHOKQZ-UHFFFAOYSA-N 4-(cyanomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CC#N)C=C1 RSGBXCFAYHOKQZ-UHFFFAOYSA-N 0.000 description 1
- ANDWZAKFRDMSAF-UHFFFAOYSA-N 4-(methoxymethylidene)oxane Chemical compound COC=C1CCOCC1 ANDWZAKFRDMSAF-UHFFFAOYSA-N 0.000 description 1
- LBTWNSSZSTVORZ-UHFFFAOYSA-N 4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-n-methylpiperidine-4-carboxamide Chemical compound N=1C(CC=2C=CC(F)=CC=2)=NOC=1C1(C(=O)NC)CCNCC1 LBTWNSSZSTVORZ-UHFFFAOYSA-N 0.000 description 1
- RFANEFRIIKJBNW-UHFFFAOYSA-N 4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-4-carbonitrile Chemical compound C1=CC(F)=CC=C1CC1=NOC(C2(CCNCC2)C#N)=N1 RFANEFRIIKJBNW-UHFFFAOYSA-N 0.000 description 1
- DMAOHWJLXMVCCH-UHFFFAOYSA-N 5-[1-benzyl-4-(methoxymethyl)piperidin-4-yl]-3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazole Chemical compound C1CC(COC)(C=2ON=C(CC=3C=CC(F)=CC=3)N=2)CCN1CC1=CC=CC=C1 DMAOHWJLXMVCCH-UHFFFAOYSA-N 0.000 description 1
- ZPNGKRXVCMUARH-UHFFFAOYSA-N 5-methyl-3-piperidin-4-yl-1,2,4-oxadiazole;hydrochloride Chemical compound Cl.O1C(C)=NC(C2CCNCC2)=N1 ZPNGKRXVCMUARH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000040717 Alpha family Human genes 0.000 description 1
- 108091071248 Alpha family Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- NKBHCIWZVPOROK-GHRIWEEISA-N C1CC(C(=O)/N=C/N(C)C)CCN1CC1=CC=CC=C1 Chemical compound C1CC(C(=O)/N=C/N(C)C)CCN1CC1=CC=CC=C1 NKBHCIWZVPOROK-GHRIWEEISA-N 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 108010061304 CXCR6 Receptors Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100021198 Chemerin-like receptor 2 Human genes 0.000 description 1
- 102000004003 Chemokine CCL11 Human genes 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102100023416 G-protein coupled receptor 15 Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000746022 Homo sapiens CX3C chemokine receptor 1 Proteins 0.000 description 1
- 101000750094 Homo sapiens Chemerin-like receptor 2 Proteins 0.000 description 1
- 101000829794 Homo sapiens G-protein coupled receptor 15 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029301 Neurological disorders of the eye Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 101150044134 US28 gene Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZONGPQSDGXCJGF-UHFFFAOYSA-N [1-benzyl-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-4-yl]methanol Chemical compound C1CC(CO)(C=2ON=C(CC=3C=CC(F)=CC=3)N=2)CCN1CC1=CC=CC=C1 ZONGPQSDGXCJGF-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- FQXNDMNLGCWIFL-VWLOTQADSA-N benzyl 1-[(3s)-3-(cyclobutanecarbonylamino)-3-phenylpropyl]piperidine-4-carboxylate Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(=O)OCC1=CC=CC=C1 FQXNDMNLGCWIFL-VWLOTQADSA-N 0.000 description 1
- BSYLXKNZZOEFHN-NRFANRHFSA-N benzyl 1-[(3s)-3-amino-3-phenylpropyl]piperidine-4-carboxylate Chemical compound C([C@H](N)C=1C=CC=CC=1)CN(CC1)CCC1C(=O)OCC1=CC=CC=C1 BSYLXKNZZOEFHN-NRFANRHFSA-N 0.000 description 1
- HNBICTHFJXARJD-UHFFFAOYSA-N benzyl 4-(3-benzyl-1,2,4-triazol-1-yl)piperidine-1-carboxylate Chemical compound C1CC(N2N=C(CC=3C=CC=CC=3)N=C2)CCN1C(=O)OCC1=CC=CC=C1 HNBICTHFJXARJD-UHFFFAOYSA-N 0.000 description 1
- QALVIZXPGUALGP-UHFFFAOYSA-N benzyl 4-(3-benzyl-5-methyl-1,2,4-triazol-1-yl)piperidine-1-carboxylate Chemical compound N=1N(C2CCN(CC2)C(=O)OCC=2C=CC=CC=2)C(C)=NC=1CC1=CC=CC=C1 QALVIZXPGUALGP-UHFFFAOYSA-N 0.000 description 1
- KCELIGHSCQKNIR-UHFFFAOYSA-N benzyl 4-[2-[(2-methylpropan-2-yl)oxycarbonyl]hydrazinyl]piperidine-1-carboxylate Chemical compound C1CC(NNC(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 KCELIGHSCQKNIR-UHFFFAOYSA-N 0.000 description 1
- DWGHTTWFCWLICZ-UHFFFAOYSA-N benzyl 4-hydrazinylpiperidine-1-carboxylate Chemical compound C1CC(NN)CCN1C(=O)OCC1=CC=CC=C1 DWGHTTWFCWLICZ-UHFFFAOYSA-N 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- BLBHAAHASZMYPI-UHFFFAOYSA-N benzyl piperidine-4-carboxylate Chemical compound C1CNCCC1C(=O)OCC1=CC=CC=C1 BLBHAAHASZMYPI-UHFFFAOYSA-N 0.000 description 1
- AZRWNJFEUSHORT-UHFFFAOYSA-N benzyl-bis(2-chloroethyl)azanium;chloride Chemical compound [Cl-].ClCC[NH+](CCCl)CC1=CC=CC=C1 AZRWNJFEUSHORT-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 239000002556 chemokine receptor agonist Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- VDALIBWXVQVFGZ-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;chloride Chemical compound [Cl-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 VDALIBWXVQVFGZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- JSBXEGSGXHGONC-UHFFFAOYSA-N ethyl 1-benzyl-4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2ON=C(CC=3C=CC(F)=CC=3)N=2)CCN1CC1=CC=CC=C1 JSBXEGSGXHGONC-UHFFFAOYSA-N 0.000 description 1
- SLMFEPBZDHRLKY-UHFFFAOYSA-N ethyl 2-(3-benzyl-1,2,4-oxadiazol-5-yl)acetate Chemical compound O1C(CC(=O)OCC)=NC(CC=2C=CC=CC=2)=N1 SLMFEPBZDHRLKY-UHFFFAOYSA-N 0.000 description 1
- MNGRBQRKDNDITH-UHFFFAOYSA-N ethyl 4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidine-4-carboxylate Chemical compound N=1C(CC=2C=CC=CC=2)=NOC=1C1(C(=O)OCC)CCNCC1 MNGRBQRKDNDITH-UHFFFAOYSA-N 0.000 description 1
- MODZVIMSNXSQIH-UHFFFAOYSA-N ethyl benzenecarboximidate;hydron;chloride Chemical compound Cl.CCOC(=N)C1=CC=CC=C1 MODZVIMSNXSQIH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- WOFDVDFSGLBFAC-UHFFFAOYSA-N lactonitrile Chemical compound CC(O)C#N WOFDVDFSGLBFAC-UHFFFAOYSA-N 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- USJUUYYGHABIBU-UHFFFAOYSA-N methanesulfonamide;hydrochloride Chemical compound Cl.CS(N)(=O)=O USJUUYYGHABIBU-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- RZWKMEPHTUARJQ-LBPRGKRZSA-N methyl (3s)-3-(3-fluorophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(=O)OC)C1=CC=CC(F)=C1 RZWKMEPHTUARJQ-LBPRGKRZSA-N 0.000 description 1
- DERXSPMWJAGZTL-ZDUSSCGKSA-N methyl (3s)-3-(cyclobutanecarbonylamino)-3-phenylpropanoate Chemical compound N([C@@H](CC(=O)OC)C=1C=CC=CC=1)C(=O)C1CCC1 DERXSPMWJAGZTL-ZDUSSCGKSA-N 0.000 description 1
- OCQYRBSHPIUCTQ-LBPRGKRZSA-N methyl (3s)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(=O)OC)C1=CC=CC=C1 OCQYRBSHPIUCTQ-LBPRGKRZSA-N 0.000 description 1
- NZGXGJORNZGEJV-VIFPVBQESA-N methyl (3s)-3-amino-3-(3-fluorophenyl)propanoate Chemical compound COC(=O)C[C@H](N)C1=CC=CC(F)=C1 NZGXGJORNZGEJV-VIFPVBQESA-N 0.000 description 1
- XKIOBYHZFPTKCZ-VIFPVBQESA-N methyl (3s)-3-amino-3-phenylpropanoate Chemical compound COC(=O)C[C@H](N)C1=CC=CC=C1 XKIOBYHZFPTKCZ-VIFPVBQESA-N 0.000 description 1
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 1
- XSNUGLQVCGENEM-UHFFFAOYSA-N methyl 3-(cyanomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CC#N)=C1 XSNUGLQVCGENEM-UHFFFAOYSA-N 0.000 description 1
- DERXSPMWJAGZTL-UHFFFAOYSA-N methyl 3-(cyclobutanecarbonylamino)-3-phenylpropanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OC)NC(=O)C1CCC1 DERXSPMWJAGZTL-UHFFFAOYSA-N 0.000 description 1
- GYKTZBZYSKZYDB-UHFFFAOYSA-N methyl 3-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)CC(N)C1=CC=CC=C1 GYKTZBZYSKZYDB-UHFFFAOYSA-N 0.000 description 1
- MTDQDWQMOPSLRM-UHFFFAOYSA-N methyl 4-(2-imino-2-methoxyethyl)benzoate Chemical compound COC(=N)CC1=CC=C(C(=O)OC)C=C1 MTDQDWQMOPSLRM-UHFFFAOYSA-N 0.000 description 1
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
- XRZGMNGGCZTNGE-UHFFFAOYSA-N methyl 4-(cyanomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CC#N)C=C1 XRZGMNGGCZTNGE-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AYTAYKXVFZPRAF-KQQUZDAGSA-N n'-[(e)-dimethylaminomethylideneamino]-n,n-dimethylmethanimidamide Chemical compound CN(C)\C=N\N=C\N(C)C AYTAYKXVFZPRAF-KQQUZDAGSA-N 0.000 description 1
- VLFMZFZQYOAQSE-UHFFFAOYSA-N n'-hydroxy-2-(3-sulfamoylphenyl)ethanimidamide Chemical compound NS(=O)(=O)C1=CC=CC(CC(=N)NO)=C1 VLFMZFZQYOAQSE-UHFFFAOYSA-N 0.000 description 1
- KQJMWYSYFJGTOC-UHFFFAOYSA-N n'-hydroxy-2-(4-sulfamoylphenyl)ethanimidamide Chemical compound NS(=O)(=O)C1=CC=C(CC(=N)NO)C=C1 KQJMWYSYFJGTOC-UHFFFAOYSA-N 0.000 description 1
- UGFRKJFFNWIUTB-UHFFFAOYSA-N n'-hydroxy-2-[3-(methanesulfonamido)phenyl]ethanimidamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC(=N)NO)=C1 UGFRKJFFNWIUTB-UHFFFAOYSA-N 0.000 description 1
- QPSFNZJGLHDENP-UHFFFAOYSA-N n'-hydroxy-2-[4-(trifluoromethyl)phenyl]ethanimidamide Chemical compound ON=C(N)CC1=CC=C(C(F)(F)F)C=C1 QPSFNZJGLHDENP-UHFFFAOYSA-N 0.000 description 1
- FVYBAJYRRIYNBN-UHFFFAOYSA-N n'-hydroxy-2-phenylethanimidamide Chemical compound ON=C(N)CC1=CC=CC=C1 FVYBAJYRRIYNBN-UHFFFAOYSA-N 0.000 description 1
- WVALRFKCJCIVBR-UHFFFAOYSA-N n'-hydroxy-4-methoxybenzenecarboximidamide Chemical compound COC1=CC=C(C(N)=NO)C=C1 WVALRFKCJCIVBR-UHFFFAOYSA-N 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- QSNCZSFNOARIDF-UHFFFAOYSA-N n-(3-oxo-1-phenylpropyl)cyclobutanecarboxamide Chemical compound C=1C=CC=CC=1C(CC=O)NC(=O)C1CCC1 QSNCZSFNOARIDF-UHFFFAOYSA-N 0.000 description 1
- LQESQOGKWZYEGA-DEOSSOPVSA-N n-[(1s)-1-phenyl-3-[4-[3-(pyridin-2-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=N1 LQESQOGKWZYEGA-DEOSSOPVSA-N 0.000 description 1
- QRCVEDJGTNLBAL-DEOSSOPVSA-N n-[(1s)-1-phenyl-3-[4-[3-(pyridin-3-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CN=C1 QRCVEDJGTNLBAL-DEOSSOPVSA-N 0.000 description 1
- RTGHHAAINNCIJX-DEOSSOPVSA-N n-[(1s)-1-phenyl-3-[4-[3-(pyridin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C([C@H](NC(=O)C1CCC1)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=NC=C1 RTGHHAAINNCIJX-DEOSSOPVSA-N 0.000 description 1
- MOHMEGZTWSKUIO-VWLOTQADSA-N n-[(1s)-1-phenyl-3-[4-[3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 MOHMEGZTWSKUIO-VWLOTQADSA-N 0.000 description 1
- DJWZWTQGQULMLW-VWLOTQADSA-N n-[(1s)-1-phenyl-3-[4-[3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 DJWZWTQGQULMLW-VWLOTQADSA-N 0.000 description 1
- OESQJOGKDGFTBW-VWLOTQADSA-N n-[(1s)-3-[4-[3-[(2,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound FC1=CC=C(F)C(CC=2N=C(ON=2)C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=C1 OESQJOGKDGFTBW-VWLOTQADSA-N 0.000 description 1
- MJCOAHJAYRRNMW-VWLOTQADSA-N n-[(1s)-3-[4-[3-[(3-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound ClC1=CC=CC(CC=2N=C(ON=2)C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=C1 MJCOAHJAYRRNMW-VWLOTQADSA-N 0.000 description 1
- QFDRZUVSIHPJIF-SANMLTNESA-N n-[(1s)-3-[4-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]cyclobutanecarboxamide Chemical compound C1=CC(C)=CC=C1CC1=NOC(C2CCN(CC[C@H](NC(=O)C3CCC3)C=3C=CC=CC=3)CC2)=N1 QFDRZUVSIHPJIF-SANMLTNESA-N 0.000 description 1
- QSNCZSFNOARIDF-ZDUSSCGKSA-N n-[(1s)-3-oxo-1-phenylpropyl]cyclobutanecarboxamide Chemical compound N([C@@H](CC=O)C=1C=CC=CC=1)C(=O)C1CCC1 QSNCZSFNOARIDF-ZDUSSCGKSA-N 0.000 description 1
- ZJWZGGZHVJECQN-UHFFFAOYSA-N n-[1-phenyl-3-[4-(1,2,4-triazol-4-yl)piperidin-1-yl]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NC(C=1C=CC=CC=1)CCN(CC1)CCC1N1C=NN=C1 ZJWZGGZHVJECQN-UHFFFAOYSA-N 0.000 description 1
- IABBFZUIRINZBY-UHFFFAOYSA-N n-[4-(cyanomethyl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C(CC#N)C=C1 IABBFZUIRINZBY-UHFFFAOYSA-N 0.000 description 1
- FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 1
- XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 1
- KKXCMMIWHOYQCM-UHFFFAOYSA-N n-benzylpiperidine-4-carboxamide Chemical compound C1CNCCC1C(=O)NCC1=CC=CC=C1 KKXCMMIWHOYQCM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- GQAOAEZHNFTLFF-UHFFFAOYSA-N phenyl acetimidate Chemical compound CC(=N)OC1=CC=CC=C1 GQAOAEZHNFTLFF-UHFFFAOYSA-N 0.000 description 1
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical class NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- YHTJXNDDGZXEJD-UQIIZPHYSA-M sodium;4-[[1-[1-[(3s)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropyl]piperidin-4-yl]-1,2,4-triazol-3-yl]methyl]benzoate Chemical compound [Na+].C([C@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)CN(CC1)CCC1N(N=1)C=NC=1CC1=CC=C(C([O-])=O)C=C1 YHTJXNDDGZXEJD-UQIIZPHYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950002920 talviraline Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BLWAGTINCIXPSB-RLWLMLJZSA-N tert-butyl (3s)-3-[benzyl-[(1r)-1-phenylethyl]amino]-3-(3-fluorophenyl)propanoate Chemical compound N([C@H](C)C=1C=CC=CC=1)([C@@H](CC(=O)OC(C)(C)C)C=1C=C(F)C=CC=1)CC1=CC=CC=C1 BLWAGTINCIXPSB-RLWLMLJZSA-N 0.000 description 1
- IKDGGSOWHJECTM-BQYQJAHWSA-N tert-butyl (e)-3-(3-fluorophenyl)prop-2-enoate Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC=CC(F)=C1 IKDGGSOWHJECTM-BQYQJAHWSA-N 0.000 description 1
- XFFKMTJDBOVLFY-UHFFFAOYSA-N tert-butyl 3-(3-benzyl-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1C1=NC(CC=2C=CC=CC=2)=NO1 XFFKMTJDBOVLFY-UHFFFAOYSA-N 0.000 description 1
- TYYCBAISLMKLMT-UHFFFAOYSA-N tert-butyl 3-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)CC(N)C1=CC=CC=C1 TYYCBAISLMKLMT-UHFFFAOYSA-N 0.000 description 1
- VBRPVLMJDKSXFS-UHFFFAOYSA-N tert-butyl 4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate Chemical compound CC1=NOC(C2CCN(CC2)C(=O)OC(C)(C)C)=N1 VBRPVLMJDKSXFS-UHFFFAOYSA-N 0.000 description 1
- MCBQMWKYDHOONN-UHFFFAOYSA-N tert-butyl 4-(5-benzyl-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(O1)=NN=C1CC1=CC=CC=C1 MCBQMWKYDHOONN-UHFFFAOYSA-N 0.000 description 1
- IAJGBPCHTIBKSG-UHFFFAOYSA-N tert-butyl 4-(5-benzyl-1-methyl-1,2,4-triazol-3-yl)piperidine-1-carboxylate Chemical compound CN1N=C(C2CCN(CC2)C(=O)OC(C)(C)C)N=C1CC1=CC=CC=C1 IAJGBPCHTIBKSG-UHFFFAOYSA-N 0.000 description 1
- OOSVMQSFMYDWFQ-UHFFFAOYSA-N tert-butyl 4-(5-benzyl-1h-1,2,4-triazol-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NNC(CC=2C=CC=CC=2)=N1 OOSVMQSFMYDWFQ-UHFFFAOYSA-N 0.000 description 1
- ITRKRVBZAWBSCY-UHFFFAOYSA-N tert-butyl 4-(5-methyl-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate Chemical compound O1C(C)=NN=C1C1CCN(C(=O)OC(C)(C)C)CC1 ITRKRVBZAWBSCY-UHFFFAOYSA-N 0.000 description 1
- UGYBDTMVFYCPLM-UHFFFAOYSA-N tert-butyl 4-(c-ethoxycarbonimidoyl)piperidine-1-carboxylate Chemical compound CCOC(=N)C1CCN(C(=O)OC(C)(C)C)CC1 UGYBDTMVFYCPLM-UHFFFAOYSA-N 0.000 description 1
- JLIKTOWFNQDEME-UHFFFAOYSA-N tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(=O)NN)CC1 JLIKTOWFNQDEME-UHFFFAOYSA-N 0.000 description 1
- GPJLSIVULOSTFW-UHFFFAOYSA-N tert-butyl 4-[(z)-n'-(2-phenylacetyl)oxycarbamimidoyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(N)=NOC(=O)CC1=CC=CC=C1 GPJLSIVULOSTFW-UHFFFAOYSA-N 0.000 description 1
- MLWSUHMQBZWYHS-UHFFFAOYSA-N tert-butyl 4-[3-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=C3OCOC3=CC=2)=NO1 MLWSUHMQBZWYHS-UHFFFAOYSA-N 0.000 description 1
- OYDSVWRRUOVARI-UHFFFAOYSA-N tert-butyl 4-[3-(1-benzofuran-5-ylmethyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=C3C=COC3=CC=2)=NO1 OYDSVWRRUOVARI-UHFFFAOYSA-N 0.000 description 1
- BPTDUWUQBKJNOQ-UHFFFAOYSA-N tert-butyl 4-[3-(2-methylpropyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound CC(C)CC1=NOC(C2CCN(CC2)C(=O)OC(C)(C)C)=N1 BPTDUWUQBKJNOQ-UHFFFAOYSA-N 0.000 description 1
- RGOKJEXQESDQMG-UHFFFAOYSA-N tert-butyl 4-[3-[(2,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C(=CC=C(F)C=2)F)=NO1 RGOKJEXQESDQMG-UHFFFAOYSA-N 0.000 description 1
- QDLUWPVOVYGGER-UHFFFAOYSA-N tert-butyl 4-[3-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C(=CC=CC=2F)F)=NO1 QDLUWPVOVYGGER-UHFFFAOYSA-N 0.000 description 1
- MGSPVWGGTZYMPE-UHFFFAOYSA-N tert-butyl 4-[3-[(3,5-difluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=C(F)C=C(F)C=2)=NO1 MGSPVWGGTZYMPE-UHFFFAOYSA-N 0.000 description 1
- ZIQODIFQDXITIG-UHFFFAOYSA-N tert-butyl 4-[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=CC(Cl)=CC=2)=NO1 ZIQODIFQDXITIG-UHFFFAOYSA-N 0.000 description 1
- FKXBXBALFWLRNC-UHFFFAOYSA-N tert-butyl 4-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1CC1=NOC(C2CCN(CC2)C(=O)OC(C)(C)C)=N1 FKXBXBALFWLRNC-UHFFFAOYSA-N 0.000 description 1
- GFXCRQSBFRDGSP-UHFFFAOYSA-N tert-butyl 4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=CC(NS(C)(=O)=O)=CC=2)=NO1 GFXCRQSBFRDGSP-UHFFFAOYSA-N 0.000 description 1
- HZNIGSIYDXZFLI-UHFFFAOYSA-N tert-butyl 4-[3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=CC(OC(F)(F)F)=CC=2)=NO1 HZNIGSIYDXZFLI-UHFFFAOYSA-N 0.000 description 1
- ORNNWOJFCCKZOI-UHFFFAOYSA-N tert-butyl 4-[3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(CC=2C=CC(=CC=2)C(F)(F)F)=NO1 ORNNWOJFCCKZOI-UHFFFAOYSA-N 0.000 description 1
- YHFUWPUJUMZXBD-UHFFFAOYSA-N tert-butyl 4-carbamoylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(N)=O)CC1 YHFUWPUJUMZXBD-UHFFFAOYSA-N 0.000 description 1
- UQADQTBQNVARAP-UHFFFAOYSA-N tert-butyl 4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1 UQADQTBQNVARAP-UHFFFAOYSA-N 0.000 description 1
- CEKQBBZOTWNKLA-SANMLTNESA-N tert-butyl N-[(1S)-3-[4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-triazol-1-yl]piperidin-1-yl]-1-phenylpropyl]carbamate Chemical compound C(C)(C)(C)OC(N[C@@H](CCN1CCC(CC1)N1N=C(N=C1)CC1=CC=C(C=C1)NS(=O)(=O)C)C1=CC=CC=C1)=O CEKQBBZOTWNKLA-SANMLTNESA-N 0.000 description 1
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OQTWRICWRDSNAB-QFIPXVFZSA-N tert-butyl n-[(1s)-3-[3-(3-benzyl-1,2,4-oxadiazol-5-yl)azetidin-1-yl]-1-phenylpropyl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)CN(C1)CC1C(ON=1)=NC=1CC1=CC=CC=C1 OQTWRICWRDSNAB-QFIPXVFZSA-N 0.000 description 1
- JGEGWLIBDZGYKF-DEOSSOPVSA-N tert-butyl n-[(1s)-3-[4-(3-benzyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1-phenylpropyl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=CC=C1 JGEGWLIBDZGYKF-DEOSSOPVSA-N 0.000 description 1
- SLQDPPNYLUUNAU-VWLOTQADSA-N tert-butyl n-[(1s)-3-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-4-(methoxymethyl)piperidin-1-yl]-1-phenylpropyl]carbamate Chemical compound C1([C@@H](NC(=O)OC(C)(C)C)CCN2CCC(CC2)(COC)C=2ON=C(CC=3C=CC(F)=CC=3)N=2)=CC=CC=C1 SLQDPPNYLUUNAU-VWLOTQADSA-N 0.000 description 1
- FEXFBHDRXAHKMW-VWLOTQADSA-N tert-butyl n-[(1s)-3-[4-[3-[[4-(methanesulfonamido)phenyl]methyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]-1-phenylpropyl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)CN(CC1)CCC1C(ON=1)=NC=1CC1=CC=C(NS(C)(=O)=O)C=C1 FEXFBHDRXAHKMW-VWLOTQADSA-N 0.000 description 1
- ZGPCDZZHEWGTEU-LBPRGKRZSA-N tert-butyl n-[(1s)-3-oxo-1-phenylpropyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](CC=O)C1=CC=CC=C1 ZGPCDZZHEWGTEU-LBPRGKRZSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Compression, Expansion, Code Conversion, And Decoders (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828420.1A GB9828420D0 (en) | 1998-12-23 | 1998-12-23 | CCR5 antagonists useful as anti-hiv agents |
GBGB9922009.7A GB9922009D0 (en) | 1999-09-18 | 1999-09-18 | CCR5 Modulators |
PCT/IB1999/001913 WO2000039125A1 (en) | 1998-12-23 | 1999-12-01 | Piperidines as ccr5 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20010478A2 true HRP20010478A2 (en) | 2002-06-30 |
Family
ID=26314900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20010478A HRP20010478A2 (en) | 1998-12-23 | 2001-06-25 | Piperidines as ccr5 modulators |
Country Status (37)
Country | Link |
---|---|
US (1) | US7217714B1 (es) |
EP (1) | EP1140920A1 (es) |
JP (2) | JP3522691B2 (es) |
KR (1) | KR20010099931A (es) |
CN (1) | CN1150192C (es) |
AP (1) | AP2001002187A0 (es) |
AR (2) | AR023345A1 (es) |
AU (1) | AU769449B2 (es) |
BG (1) | BG105709A (es) |
BR (1) | BR9916585A (es) |
CA (1) | CA2350573C (es) |
CR (1) | CR6393A (es) |
CZ (1) | CZ20012297A3 (es) |
DZ (1) | DZ2978A1 (es) |
EA (1) | EA200100588A1 (es) |
EE (1) | EE200100344A (es) |
GE (1) | GEP20043161B (es) |
HK (1) | HK1039942B (es) |
HN (1) | HN1999000221A (es) |
HR (1) | HRP20010478A2 (es) |
HU (1) | HUP0104910A3 (es) |
ID (1) | ID29031A (es) |
IL (1) | IL143510A0 (es) |
IS (1) | IS5941A (es) |
MA (1) | MA26715A1 (es) |
NO (1) | NO20013149L (es) |
NZ (1) | NZ511796A (es) |
OA (1) | OA11732A (es) |
PA (1) | PA8488101A1 (es) |
PE (1) | PE20001371A1 (es) |
PL (1) | PL349091A1 (es) |
SK (1) | SK8762001A3 (es) |
TN (1) | TNSN99253A1 (es) |
TR (2) | TR200200938T2 (es) |
UY (1) | UY25869A1 (es) |
WO (1) | WO2000039125A1 (es) |
YU (1) | YU40701A (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
EP1118858A3 (en) * | 2000-01-12 | 2003-07-09 | Pfizer Limited | Assay method |
RS51436B (en) * | 2000-05-26 | 2011-04-30 | Pfizer Inc. | DERIVATIVES TRIAZOLIL TROPANA KAO MODULATORS CCR5 |
US6511994B2 (en) | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
US6531484B2 (en) | 2000-10-11 | 2003-03-11 | Merck & Co., Inc. | Pyrrolidine modulators of CCR5 chemokine receptor activity |
US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
US7202259B2 (en) | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
WO2004052862A1 (ja) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
DE60318891T2 (de) | 2002-12-13 | 2009-01-22 | Smithkline Beecham Corp. | Cyclopropylverbindungen als ccr5 antagonisten |
US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US7498323B2 (en) | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
CA2579609A1 (en) | 2003-09-10 | 2005-03-17 | Virochem Pharma Inc. | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
JP2007509959A (ja) | 2003-10-28 | 2007-04-19 | アムゲン インコーポレイティッド | トリアゾール化合物およびそれに関連する使用法 |
BRPI0506548A (pt) | 2004-01-30 | 2007-05-02 | Euro Celtique Sa | métodos para produzir compostos de 4-tetrazolil-4-fenilpiperidina |
TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
RU2006146608A (ru) | 2004-06-09 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ |
SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
CN1980901A (zh) | 2004-06-30 | 2007-06-13 | 万有制药株式会社 | 联芳基衍生物 |
KR101231466B1 (ko) | 2004-09-13 | 2013-02-07 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제 |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
WO2006138350A2 (en) * | 2005-06-15 | 2006-12-28 | Anormed Inc. | Chemokine receptor binding compounds |
WO2006136917A1 (en) * | 2005-06-22 | 2006-12-28 | Pfizer Limited | Triazolylpiperidine derivatives and use thereof in therapy |
HUP0500920A2 (en) * | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
DK1942108T3 (da) | 2005-10-28 | 2013-12-09 | Ono Pharmaceutical Co | Forbindelse indeholdende basisk gruppe samt anvendelse deraf |
EP1961744B1 (en) | 2005-11-18 | 2013-04-17 | Ono Pharmaceutical Co., Ltd. | Basic group-containing compound and use thereof |
JP2009518384A (ja) * | 2005-12-08 | 2009-05-07 | ファイザー・リミテッド | 化合物 |
CN101443322A (zh) | 2006-03-10 | 2009-05-27 | 小野药品工业株式会社 | 含氮杂环衍生物及含有该衍生物作为活性成分的药物 |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
JP5245827B2 (ja) | 2006-07-31 | 2013-07-24 | 小野薬品工業株式会社 | スピロ結合した環状基を含有する化合物およびその用途 |
DE602007013573D1 (de) | 2006-08-16 | 2011-05-12 | Hoffmann La Roche | Nicht-nukleosidische reverse-transkriptase-hemmer |
ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
WO2009010480A1 (en) * | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | 1-{2-[(diphenyl)amino]-ethyl}-piperidine-4-carboxylic acid benzylamide derivatives and related compounds as ccr5 agonists for the treatment of immune and inflammatory diseases |
ES2593706T3 (es) | 2007-08-31 | 2016-12-12 | Purdue Pharma Lp | Compuestos de piperidina, de tipo quinoxalina sustituida, y usos de los mismos |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
CA2785191A1 (en) | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
CN103420998A (zh) * | 2012-05-16 | 2013-12-04 | 苏州爱斯鹏药物研发有限责任公司 | 一种新型噁二唑衍生物的合成方法 |
CN104744451A (zh) * | 2013-12-30 | 2015-07-01 | 中国科学院上海药物研究所 | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 |
CN110628021B (zh) * | 2019-09-23 | 2022-03-18 | 北京理工大学 | 一种侧链型磺化聚喹喔啉及其质子交换膜 |
CN110759902B (zh) * | 2019-11-01 | 2022-04-22 | 海南一龄医疗产业发展有限公司 | Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
CN113999103A (zh) * | 2021-11-26 | 2022-02-01 | 八叶草健康产业研究院(厦门)有限公司 | 一种α-羟基-环丁烷甲酸的制备方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9100505D0 (en) * | 1991-01-10 | 1991-02-20 | Shell Int Research | Piperidine derivatives |
GB9125900D0 (en) | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
GB9502644D0 (en) * | 1995-02-10 | 1995-03-29 | Zeneca Ltd | Heterocyclic derivatives |
GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
WO1997024325A1 (en) * | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
EP0920306A2 (en) * | 1996-07-12 | 1999-06-09 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6323206B1 (en) * | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU5604998A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
AU5803398A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
AU6133098A (en) | 1997-01-21 | 1998-08-07 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
EP1009405A4 (en) | 1997-08-28 | 2001-05-09 | Merck & Co Inc | MODULATORS OF PYRROLIDINE AND PIPERIDINE OF CHEMOKINE RECEPTOR ACTIVITY |
AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
WO1999037619A1 (en) * | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
-
1999
- 1999-11-30 US US09/451,826 patent/US7217714B1/en not_active Expired - Fee Related
- 1999-12-01 SK SK876-2001A patent/SK8762001A3/sk unknown
- 1999-12-01 AU AU12904/00A patent/AU769449B2/en not_active Ceased
- 1999-12-01 YU YU40701A patent/YU40701A/sh unknown
- 1999-12-01 EA EA200100588A patent/EA200100588A1/ru unknown
- 1999-12-01 EE EEP200100344A patent/EE200100344A/xx unknown
- 1999-12-01 JP JP2000591036A patent/JP3522691B2/ja not_active Expired - Fee Related
- 1999-12-01 BR BR9916585-6A patent/BR9916585A/pt not_active Application Discontinuation
- 1999-12-01 KR KR1020017008078A patent/KR20010099931A/ko active Search and Examination
- 1999-12-01 EP EP99956267A patent/EP1140920A1/en not_active Withdrawn
- 1999-12-01 WO PCT/IB1999/001913 patent/WO2000039125A1/en active IP Right Grant
- 1999-12-01 TR TR2002/00938T patent/TR200200938T2/xx unknown
- 1999-12-01 CN CNB998149810A patent/CN1150192C/zh not_active Expired - Fee Related
- 1999-12-01 OA OA1200100160A patent/OA11732A/en unknown
- 1999-12-01 CZ CZ20012297A patent/CZ20012297A3/cs unknown
- 1999-12-01 GE GEAP19995957A patent/GEP20043161B/en unknown
- 1999-12-01 AP APAP/P/2001/002187A patent/AP2001002187A0/en unknown
- 1999-12-01 NZ NZ511796A patent/NZ511796A/en unknown
- 1999-12-01 IL IL14351099A patent/IL143510A0/xx unknown
- 1999-12-01 PL PL99349091A patent/PL349091A1/xx not_active Application Discontinuation
- 1999-12-01 HU HU0104910A patent/HUP0104910A3/hu unknown
- 1999-12-01 CA CA002350573A patent/CA2350573C/en not_active Expired - Fee Related
- 1999-12-01 TR TR2001/01867T patent/TR200101867T2/xx unknown
- 1999-12-01 ID IDW00200101365A patent/ID29031A/id unknown
- 1999-12-15 PE PE1999001255A patent/PE20001371A1/es not_active Application Discontinuation
- 1999-12-15 AR ARP990106427A patent/AR023345A1/es unknown
- 1999-12-21 UY UY25869A patent/UY25869A1/es unknown
- 1999-12-22 TN TNTNSN99253A patent/TNSN99253A1/fr unknown
- 1999-12-22 DZ DZ990278A patent/DZ2978A1/xx active
- 1999-12-22 MA MA25869A patent/MA26715A1/fr unknown
- 1999-12-23 PA PA19998488101A patent/PA8488101A1/es unknown
- 1999-12-23 HN HN1999000221A patent/HN1999000221A/es unknown
- 1999-12-28 AR ARP990106792A patent/AR023363A1/es not_active Application Discontinuation
-
2001
- 2001-05-15 IS IS5941A patent/IS5941A/is unknown
- 2001-06-14 CR CR6393A patent/CR6393A/es not_active Application Discontinuation
- 2001-06-22 NO NO20013149A patent/NO20013149L/no not_active Application Discontinuation
- 2001-06-25 HR HR20010478A patent/HRP20010478A2/hr not_active Application Discontinuation
- 2001-07-16 BG BG105709A patent/BG105709A/xx unknown
-
2002
- 2002-02-27 HK HK02101506.3A patent/HK1039942B/zh not_active IP Right Cessation
-
2003
- 2003-10-20 JP JP2003358714A patent/JP2004099618A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20010478A2 (en) | Piperidines as ccr5 modulators | |
JP3779111B2 (ja) | Ccr5モジュレーター | |
US6586430B1 (en) | CCR5 modulators | |
KR101078505B1 (ko) | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제 | |
JP5837482B2 (ja) | ピラゾールオキサジアゾール誘導体 | |
JP6695335B2 (ja) | RORγtのモジュレーターとしてのアミド置換チアゾール | |
JPWO2007105637A1 (ja) | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 | |
IL144512A (en) | A spontaneously dispersed medicinal preparation, a capsule containing it and its use in the preparation of drugs for the treatment of cancer | |
KR20060003353A (ko) | 케모킨 수용체의벤족사지닐-아미도사이클로펜틸-헤테로사이클릭 조절제 | |
MXPA01006569A (es) | Piperidinas como moduladores de ccr5 | |
ES2362711T3 (es) | Azabicicloalcanos como moduladores de ccr5. | |
MXPA99012102A (es) | Moduladores del ccr5 | |
MXPA01006523A (es) | Moduladores de ccr5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |